Jingfeng Pharmaceutical(SZ:000908) 智通财经网·2025-10-21 13:15Core Viewpoint - ST Jinfeng (000908.SZ) has received a court ruling from Changde Intermediate Court accepting the creditors' restructuring application, indicating significant financial distress and potential operational changes for the company [1] Group 1: Court Ruling and Restructuring - The Changde Intermediate Court has accepted the creditors' restructuring application for ST Jinfeng, appointing Beijing Zhonglun Law Firm as the administrator [1] - The court's decision is documented in the civil ruling (2024) Xiang 07 Po Shen 7 and the decision (2025) Xiang 07 Po 15 [1] Group 2: Stock Market Implications - Following the court's ruling, ST Jinfeng's stock will be subject to delisting risk warning, effective from October 23, 2025, with the stock name changing to "*ST Jinfeng" while the security code remains "000908" [1] - The daily price fluctuation limit for the stock will continue to be set at 5% [1] - The stock will be suspended from trading on October 22, 2025, and will resume trading on October 23, 2025 [1]